Sclerostin inhibition for osteoporosis - A new approach

New England Journal of Medicine

Volumn 370, Issue 5, 2014, Pages 476-477

  Becker, Carolyn B ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; PARATHYROID HORMONE[1-34]; ROMOSOZUMAB; SCLEROSTIN;

BONE DENSITY; BONE METABOLISM; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FRACTURE; HUMAN; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL;

EID: 84893145270     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1315500     Document Type: Editorial

References (8)

1. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434-41. (Pubitemid 32402100)
2. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014;370:412-20.
3. Horwitz MJ, Augustine M, Kahn L, et al. A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study. J Bone Miner Res 2013;28:2266-76.
4. Brixen K, Chapurlat R, Cheung AM, et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab 2013;98:571-80.
5. Cosman F, Eriksen EF, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 2011;26:503-11.
6. Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 2013;382: 50-6.
7. Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005;353:566-75. (Pubitemid 41138938)
8. Schafer AL, Sellmeyer DE, Palermo L, et al. Six months of parathyroid hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and Ibandronate Combination Study (PICS) randomized trial. J Clin Endocrinol Metab 2012;97:3522-9.